Wednesday, February 8, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Pfizer Partners with Tiny Biotech to Research Next-Gen Covid Treatment

in News, Uncategorized
Pfizer partners with tiny biotech to research next-gen covid treatment
Share on FacebookShare on Twitter

On December 6th, Pfizer (NYSE: PFE) announced a research collaboration and exclusive license agreement with Clear Creek Bio — a 10-person biotech that has an office in Cambridge, MA, but operates fully remotely. This program will expand Pfizer’s innovative anti-infective pipeline and, if successful, will complement Pfizer’s existing portfolio of COVID-19 products with direct-acting antiviral agents against different SARS-CoV-2 targets.

“COVID-19 has proven to be a devastating and highly unpredictable disease, one with the potential to remain a global health concern for years to come,” said Charlotte Allerton, Chief Scientific Officer, Anti-Infectives and Head of Medicine Design, of Pfizer. “It is critical that we try to stay ahead of the virus, continuing to advance clinical development opportunities for our current oral therapy as well as innovating through our internal programs and strategic partnerships to bring forward additional monotherapy and/or combination treatment candidates that we believe may play a role in the ongoing fight against COVID-19.”

Under the terms of the agreement, the two companies will work together to identify an essential enzyme (PLpro), which plays an important role in viral replication. At which time Pfizer will be solely responsible for further development and commercialization activities. Clear Creek Bio will receive an undisclosed upfront payment and will be eligible to receive additional potential milestone payments plus royalties on future product sales.

Tags: Biotech industryCOVID-19Pfizer

Related Posts

Super bowl betting projected to reach $16 billion this year
News

Super Bowl betting projected to reach $16 billion this year

Ev batteries getting second life on california power grid
News

EV batteries getting second life on California power grid

Microsoft investigates outlook outage as users face issues
News

Microsoft investigates Outlook outage as users face issues

Public storage makes $11 billion hostile bid for life storage
News

Public Storage makes $11 billion hostile bid for Life Storage

Drug companies face covid cliff in 2023 as sales set to plummet
News

Drug companies face COVID cliff in 2023 as sales set to plummet

Dell to slash over 6,000 jobs amid ‘uncertain market future’
News

Dell to slash over 6,000 jobs amid ‘uncertain market future’

U. S. Reports blowout job growth; unemployment rate lowest since 1969
News

U.S. reports blowout job growth; unemployment rate lowest since 1969

Honda issues ‘do not drive’ warning for 8,200 u. S. Vehicles over air bag risks
News

Honda issues ‘Do Not Drive’ warning for 8,200 U.S. vehicles over air bag risks

Dollar jumps as u. S. Employers add more jobs than expected in january
News

Dollar jumps as U.S. employers add more jobs than expected in January

Mortgage rates fall to the 5% range for first time since september
News

Mortgage rates fall to the 5% range for first time since September

No Result
View All Result

Recent Posts

  • Super Bowl betting projected to reach $16 billion this year
  • EV batteries getting second life on California power grid
  • 4 Surprises All Leaders Face
  • What’s hot this year in supply chain technology
  • Microsoft investigates Outlook outage as users face issues

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Editor-In-Chief – caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In